Early experience managing intravascular coagulum using polidocanol endovenous microfoam: Risk factor analysis.

ObjectiveA single-center retrospective cohort study was conducted to identify potential risk factors that lead to increased incidence of intravascular coagulum (IC) observed in clinical practice using polidocanol endovenous microfoam (PEM 1%, Varithena [polidocanol injectable microfoam], Boston Scientific, Marlborough, Mass).MethodsPatients ( = 119) who received polidocanol endovenous microfoam (PEM) treatment for chronic venous insufficiency between December 2021 and January 2024 at a private outpatient vascular surgery clinic were observed to identify potential risk factors in the development of IC. The patients were stratified into two groups: IC ( = 16) versus non-IC ( = 103).

Early experience with diclofenac topical gel for moderate to severe postablation phlebitis.

Objective: Oral (PO) nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used to treat phlebitis and thrombus extension postendovenous ablation. Few studies have evaluated diclofenac topical gel for treating postablation phlebitis. This study assesses diclofenac 1% topical gel as a first-line treatment for patients with moderate to severe phlebitis after ablation.